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Pharmacy students’ attitudes and perceptions toward pharmacogenomics
education
Abstract
Purpose
To evaluate final-year pharmacy students’ perceptions toward pharmacogenomics education, their
attitudes on its clinical relevance, and their readiness to use such knowledge in practice.
Methods
A 19-question survey was developed and modified from prior studies and was pretested on a small group
of pharmacogenomics faculty and pharmacy students. The final survey was administered to 978 finalyear pharmacy students in 8 school/colleges of pharmacy in New York and New Jersey between January
and May 2017. The survey targeted 3 main themes: perceptions toward pharmacogenomics education,
attitudes toward the clinical relevance of this education, and the students’ readiness to use knowledge of
pharmacogenomics in practice.
Results
With a 35% response rate, the majority (81%) of the 339 student participants believed that
pharmacogenomics was a useful clinical tool for pharmacists, yet only 40% felt that it had been a relevant
part of their training. Almost half (46%) received only 1–3 lectures on pharmacogenomics and the
majority were not ready to use it in practice. Survey results pointed toward practice-based trainings such
as pharmacogenomics rotations as the most helpful in preparing students for practice.
Conclusions
Final-year student pharmacists reported varying exposure to pharmacogenomics content in their
pharmacy training and had positive attitudes toward the clinical relevance of the discipline, yet they
expressed low confidence in their readiness to use this information in practice.
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Abstract:
Purpose: To evaluate final year pharmacy students’ perceptions towards pharmacogenomics
education; their attitudes on its clinical relevance; and their readiness to use such knowledge in
practice.
Methods: A 19-question survey was developed and modified from prior studies and was
pretested on a small group of pharmacogenomics faculty and pharmacy students. The final
survey was administered to 978 final year pharmacy students in eight school/colleges of
pharmacy in New York and New Jersey between January and May 2017. The survey targeted
three main themes: perceptions toward pharmacogenomics education, attitudes towards the
clinical relevance of this education and the students’ readiness to use knowledge of
pharmacogenomics in practice.
Results: With a 35% response rate, the majority (81%) of the 339 students participants believed
that pharmacogenomics is a useful clinical tool for pharmacists yet only 40% felt that it had been
a relevant part of their training. Almost half (46%) received only 1 – 3 lectures on
pharmacogenomics and the majority are not ready to use it in practice. Survey results pointed
towards practice-based trainings such as pharmacogenomics rotations as the most helpful in
preparing students for practice.
Conclusions: Most of the final year student pharmacists had some exposure to
pharmacogenomics content in their training and positive attitudes towards the clinical relevance
of the discipline; however an overwhelming majority expressed low confidence in their readiness
to utilize this information in practice. Hence, practice-based training opportunities taught by
well-trained faculty may be needed to prepare future pharmacists in this discipline.
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Introduction
Pharmacogenomics is the study of how an individual’s genome can influence his or her
response to drugs.(1) To date, over 200 FDA-approved medications have pharmacogenomics
product-label changes and polymorphisms in genes that encode drug-metabolizing enzymes
make up 80% of these product label updates.(2)

However, widespread adoption into clinical

practice has been lagging behind the technological advances and research discoveries.
For decades, pharmacists have played pivotal roles in health care to optimize drug
therapy while minimizing and/or preventing adverse drug events. Pharmacists’ extensive
knowledge of pharmacotherapy and their skillsets in therapy optimization uniquely positions
them to assume key functions and leadership in the clinical implementation of
pharmacogenomics.(3) The 2015 American Society of Health-System Pharmacists (ASHP)
statement on the Pharmacist’s Role in Clinical Pharmacogenomics not only affirmed the
esteemed professional society’s support of pharmacogenomics but it also highlighted five
responsibilities of pharmacists in this specialty. Advocating for the rational and routine use of
pharmacogenomics testing, providing test results interpretation; and educating providers and
patients on clinical application of pharmacogenomics are few of the aforementioned roles of
pharmacists.(4)
In a survey of 303 pharmacists, 65% believed that pharmacists need to be knowledgeable
about the appropriate use of pharmacogenomics testing however, nearly the same number of
respondents felt inadequately prepared to use the results of pharmacogenomics tests in
practice.(5) This sentiment has been reported by others as well.(6-9) Reports in 2005
demonstrated that only 39% of pharmacy schools included pharmacogenomics content in their
curricula.(10) Fast forward to 2010, and Murphy et al reported an impressive improvement with
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90% of schools reporting curricula adoption of pharmacogenomics content.(11) In the Murphy
report, the authors also reported varying degrees of content coverage among the schools and
more than half had no plans for faculty development in pharmacogenomics.(11)
The marked increase in the number of pharmacy schools with pharmacogenomics
training may be attributed to the efforts of the Accreditation Council for Pharmacy Education
(ACPE) and the American Association of Colleges of Pharmacy (AACP) since the 2005 report.
The ACPE issued pharmacogenomics content requirements for all pharmacy schools effective
July 2007.(12) Moreover, the 2008 AACP House of Delegates approved resolutions that called
for training and curricula modifications to address implications of personalized medicine and
biotechnology as well as tailored faculty training in these disciplines.(13)
It has been a decade since the initial recommendation to focus on pharmacogenomics
training in our schools of pharmacy and as such we sought to investigate how the educational
strategies and increased training have affected the newly graduating pharmacists. The objective
of this study was to assess 2017 final year pharmacy students’ perceptions and attitudes on
pharmacogenomics and their readiness to incorporate it into their practice as pharmacists.

Methods
Survey Participants
All eleven schools/colleges of pharmacy in New York, New Jersey and Connecticut were invited
however three schools did not respond and were therefore excluded from the study. The eight
schools that participated are Albany College of Pharmacy and Health Sciences, Touro College of
Pharmacy, St. John Fisher College Wegmans School of Pharmacy, D’Youville College School of
Pharmacy, Fairleigh Dickinson University, St. John’s University, Long Island University Arnold
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& Marie Schwartz College of Pharmacy and University at Buffalo School of Pharmacy and
Pharmaceutical Sciences. The appropriate Human Subjects Protection Program Institutional
Review Board approvals were granted to all participating schools. In all, 978 final year students
(Class of 2017) were eligible to participate in the survey.

Design
This was a descriptive study that employed a 19-question survey developed and modified
from prior studies (11, 14) to assess participant demographics and three main themes: (1) the
students’ attitudes towards pharmacogenomics education; (2) their perceptions on the clinical
relevance of pharmacogenomics; and (3) their readiness to adopt it into their practice. A fivepoint likert-scale ranging from strongly agree to strongly disagree was used to score the
responses. A pretest of the survey tool was conducted with four academic pharmacists involved
in pharmacogenomics research and didactic training as well as three pharmacy students
undergoing pharmacogenomics advanced pharmacy practice experiential (APPE) rotation. All
“pre-testers” provided feedback on content, length, clarity and utility of the survey tool which
was then used to refine the final set of questions. Additionally, the authors reviewed and
approved the questionnaire before it was administered. The survey was administered
electronically via www.surveymonkey.com between January and May 2017 and faculty-student
champions from each of the participating schools deployed the link to the questionnaire to the
graduating class of their respective schools. The participants were given 8 weeks to complete the
survey initially. After that, the deadline for completion was extended for an additional four
weeks. Two reminder emails were sent by the faculty-student champions in four week intervals.
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Moreover, the faculty champions provided additional information on their respective schools and
the nature of the PGx courses offered.
Statistical Analysis
Survey data was collected using surveymonkey.com and interpreted using a range of
descriptive statistical methods, such as cross-tabulations, comparisons of means and standard
deviations across multinomial variables, and data visualization. Ordinal logistic regression was
used to estimate the overall main effects of certain demographic predictors, which were
converted to ordered categorical variables, on the survey response outcomes. All statistical
analyses were conducted in SPSS 23 and R.

Results
Student Demographics
Of 978 students eligible for the study, 339 (35%) students completed the survey. Table 1
summarizes the relevant demographics. The respondents were mostly females (n= 213, 63%). A
majority were between the ages of 21 and 25, (n=194, 57%) and 26 and 30 years (n =106, 31%).
High school was the most common educational level completed by the respondents prior to
matriculating to pharmacy school as reported by 147 (43%) students and 158 (47%) plan to
pursue community pharmacy opportunities post-graduation.
Description of the Pharmacogenomics Educational Opportunities at the Participating Schools
As shown in Table 2, pharmacogenomics is integrated through other courses at two
schools; offered as a standalone course in four schools and as both integrated and standalone in
the remaining two schools of pharmacy. Of those with standalone courses, four require it for all
their students and two offer it as an elective class. Notably, only two PGx faculty members have
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been formally trained in pharmacogenomics, while others have undergone varying degrees of
training. The learning objectives differ across schools and an elective PGx APPE rotation is
available to students from three of the participating schools.
Exposure to pharmacogenomics education
The respondents were queried on their exposure to pharmacogenomics content in their
pharmacy school curricula (Figure 1). One hundred and fifty-six (46%) were exposed to 1 – 3
pharmacogenomics lectures, 96 (28%) completed a required pharmacogenomics course, 20 (6%)
took an elective pharmacogenomics course, 8 (2%) completed a pharmacogenomics APPE
rotation, 39 (12%) did not receive any pharmacogenomics training and 19 (6%) did not respond
to this question.
Perception on the Clinical Relevance of Pharmacogenomics
Four questions were posed to investigate the perceived clinical utility and relevance of
pharmacogenomics among the final year student pharmacists (Table 3). Majority (81%, n=273)
believed that pharmacogenomics is a useful tool that pharmacists and medical professionals can
use to optimize medication efficacy and/or prevent adverse events and more than half (63%,
n=234) affirmed that it is an integral part of the pharmacy profession. Sixty-one percent (n=205)
perceived that pharmacogenomics may be an integral part of their practice as pharmacists and
slightly more (69%, n=234) predicted that they may encounter pharmacogenomics-related
questions during their practice as pharmacists.
Attitudes towards pharmacogenomics education
Approximately seventy-one percent (n = 239) of the respondents believe that
pharmacogenomics should be covered in detail in all schools and colleges of pharmacy;
however, only 40% (n=136) felt that it had been a relevant part of their Doctor of Pharmacy
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curriculum. Moreover, 51% (n=175) agreed that final year pharmacy students should be required
to have substantial knowledge of pharmacogenomics prior to graduation and 56% (n=188)
indicated their intentions of reading pharmacogenomics-related literature post-graduation
especially those that pertain to their respective practices and specialties (Table 2).
The students’ past exposure to pharmacogenomics training content was significantly
associated with their attitudes towards pharmacogenomics education. Pharmacogenomics
training (Figure 1) was converted into an ordered categorical variable, with the lowest level
being no exposure to pharmacogenomics in pharmacy school (n = 39), followed by 1-3 lectures
or seminars (n=156), elective pharmacogenomics course (n=20), required pharmacogenomics
course (n=96), and finally the highest level being pharmacogenomics APPE rotation (n= 8). This
measure of pharmacogenomics training was significantly associated with more agreement to
three of the four questions assessing attitudes towards pharmacogenomics education (Figure 2).
Readiness to Use Pharmacogenomics Knowledge in Practice
As proposed by the ASHP (4), pharmacists should know medications with
pharmacogenomics implications, the associated tests and their interpretations as well as
recommended therapeutic modifications for genetically “high-risk” individuals. To this end, we
asked the final year student pharmacists if they knew at least ten medications that the FDA either
requires or recommends pharmacogenomics testing prior to use (Table 3). Only 32% (n=108)
responded affirmatively while 44% (n=150) did not know at least ten of such medications.
Furthermore, when queried on their ability to recommend the appropriate pharmacogenomics
tests for the medications that require it, only 21% (n=72) stated they could and about a third
(27%, n=91)) reported having the ability to accurately interpret pharmacogenomics tests. Again,
32% (n=107) felt knowledgeable to recommend alternative therapies and/or dose changes based
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on pharmacogenomic results.. Lastly, 62% (n=209) were not aware of the Clinical
Pharmacogenetics Implementation Consortium’s (CPIC) guidelines which provide a clinical
recommendations to clinicians on how to use genetic information to guide medication selection
and dosing.(15)
As expected, the students’ past exposure to pharmacogenomics content in their curricula
was strongly associated with increased agreement with the statements about readiness to use
pharmacogenomics in practice (Figure 3). More exposure to pharmacogenomics was correlated
with the students’ knowledge of at least ten medications needing pharmacogenomic testing
(β=0.349, 95% CI: 0.231-0.468); their ability to recommend appropriate pharmacogenomic tests
for such medications (β=0.251, 95% CI: 0.128-0.375); their ability to accurately interpret these
tests (β=0.363, 95% CI: 0.244-0.482); their knowledge of

the appropriate therapeutic

recommendations based on the pharmacogenomics test results (β =0.342, 95% CI: 0.237-0.448);
and their awareness of CPIC guidelines (β=0.313, 95% CI: 0.206-0.420).

Discussion:
Clinical applications of pharmacogenomics are increasingly gaining acceptance as
evidenced by the National Institutes of Health National Human Genome Research Institute
(NIH/NHGRI) – funded consortia focused on developing tools and clinical implementation
strategies (16-18) and the availability of databases such as the FDA Table of Biomarkers(19) and
the Pharmacogenomics Knowledge Base: www.pharmgkb.org(20).
Pharmacists are distinctively qualified medical professionals to lead translational
pharmacogenomics and assume essential roles in its education and sustained adoption in
professional curricula (3). Of the 339 participants in this study, 82% had been exposed to

12

pharmacogenomics content in varying degrees throughout their pharmacy school program
ranging from 1 – 3 lectures to several weeks of pharmacogenomics APPE rotation experience.
This finding sadly affirms the 2010 study by Murphy et al., in which 67 (89%) colleges/schools
of pharmacy reported having pharmacogenomics content in their doctor of pharmacy curricula
albeit the dedicated didactic hours differed greatly from school to school (11). In that study, 28
schools (41%) dedicated 10 or fewer hours, while 29 (42%) reported 11 to 30 didactic hours for
pharmacogenomics. A decade later, Murphy et al.’s findings still resonate as demonstrated in the
present study. Almost half of the final year students in our survey (46%) encountered
pharmacogenomics content in 1 – 3 lectures, and approximately 12% received no
pharmacogenomics instruction throughout their pharmacy school tutelage. In all, 40% noted that
pharmacogenomics has been a relevant part of their pharmacy training. This is almost a four-fold
boost from the 2011 finding by McCullough and colleagues in which only 10% of surveyed
pharmacists stated that pharmacogenomics had been a relevant component of their pharmacy
education(5).
From this study and others, it is clear pharmacists believe that pharmacogenomics is a
relevant tool to optimize patient care however, majority are not comfortable in their abilities to
utilize it in their practice (5, 6, 14, 21). The current study and others also confirm that
educational opportunities available to student pharmacists in their training may not be sufficient
to resolve this issue. Seventy-one percent of the students’ believe that it should be covered in
detail in pharmacy curricula; 52% state that pharmacists should be required to have substantial
knowledge in pharmacogenomics prior to graduation; and 56% intend to continue seeking
educational opportunities in this discipline post-graduation. Clearly, a great number of the
students want this information.
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There are two main reasons for the inadequate training in pharmacogenomics. The first
is the lack of well-trained educators to introduce content that addresses core competencies. In our
study, 25% of the faculty members were formally trained in pharmacogenomics while the others
completed coursework, certificate programs and were exposed through involvement in
pharmacogenomics research (Table 2). Although a few were clinical faculty, none is actively
practicing in pharmacogenomics.
University

of

California

San

Diego

Pharmacogenomics

Education

Program

(PharmGenEd) (22), University of Pittsburgh’s Test2Learn(23), University of Florida (UF)
Health Personalized Medicine Program graduate and certificate training program (24) and the
University of Colorado Pharmacogenomics Certificate Program (25) are all excellent
opportunities for pharmacy school faculty to receive hands-on training in pharmacogenomics
either in person or virtually. Some programs provide a shared curriculum that may be adopted in
various schools and some use the train-the-trainer methods to provide the best results. In all,
these avenues were designed for educators and practitioners who are interested in using
pharmacogenomic information in their practice to educate the next generation or optimize patient
outcomes respectively. The leadership of colleges of pharmacy should invest in their faculty to
participate in these programs especially those who are in charge of providing the didactic
lectures on pharmacogenomics. Moreover, faculty members in this position should be aware of
the newly updated pharmacogenomics core competencies in pharmacy practice (26) and
resources(15, 20) to better instruct their students in the likely event that they encounter examples
that may not have been covered in their courses. Of note, CPIC guidelines were unknown to 62%
of the respondents in our study which highlights the need for CPIC and other pharmacogenomics
resource leaders to consider expanding their reach beyond practicing clinicians to trainees.
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Another proposed strategy for overcoming this challenge is to incorporate pharmacogenomics
exposure early in the Pharm.D curriculum through the foundational courses and into practicebased therapeutic courses, Introductory Pharmacy Practice Experiences (IPPE) and APPEs.(27)
In addition to the learning objectives in Table 2, other training content to be considered include
but not limited to online resources(28), utilization of electronic health records in
pharmacogenomics, potential implications with over-the-counter medications and herbal
therapies, reimbursement, and ethical, legal and social issues.
The second challenge is the lack of experiential and practice-based opportunities to
engage the students in real-life applications of pharmacogenomics. Formea and colleagues
reported marginal retention of educational objectives among practicing pharmacists after two
months of providing a fundamental pharmacogenomics education program accredited by ACPE
for continued education (29). They concluded that education in this topic area will require more
effort to increase knowledge and comfort in dealing with its clinical applications

as

demonstrated by Galvez-Peralta and colleagues in the School of Pharmacy in West Virginia
University(30). . Our findings support this statement and demonstrate that the extent of
pharmacogenomics educational exposure and use of practice-based scenarios for teaching may
play an important role in preparing the students for the practice setting (31). Final year students
who were enrolled in pharmacogenomics APPE rotations were more likely to be prepared to
apply pharmacogenomics knowledge in practice than those from the other training methods
(Figure 3). To the best of our knowledge, there are two pharmacogenomics APPE rotation
opportunities in the New York / New Jersey region; at Mount Sinai (32) and Touro College of
Pharmacy; and a handful of others across the country with very limited openings for students
annually. Mount Sinai offers an elective rotation to final year student pharmacists from two New
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York schools as well as post-graduate year one (PGY1) and post-graduate year two (PGY2)
pharmacy residents in the Mount Sinai Health System. Of note, it is a required rotation for PGY2
oncology pharmacy residents at The Mount Sinai Hospital. This training is a combination of
topic and patient case discussions, development of clinical decision support content and
stakeholder educational tools and personal genotyping.

Furthermore, the ASHP Online

Residency Directory (https://accred.ashp.org/aps/pages/directory/residencyProgramSearch.aspx)
lists three accredited PGY2 clinical pharmacogenomics residencies. With approximately fifteen
thousand new graduates annually (33), the training spots identified here are not nearly enough to
accommodate the need. School leaderships should make every effort to hire newly trained
pharmacogenomics experts into positions that provide both the didactic and the experiential
examples for students. Although, establishing a specialty pharmacogenomics residency is not
feasible at most institutions, partnering with health systems that are implementing
pharmacogenomics(32, 34, 35) and assigning faculty liaisons and/or designing student rotation
opportunities

may

be

possible

and

should

be

considered.

Furthermore, the strength of the relationship observed between the exposure to
pharmacogenomics content and perceived readiness to apply in practice may be limited by the
subjective nature of the survey. Also, this project is not in a position to accurately assess whether
the responses provided are an accurate representation of the students’ knowledge. Future studies
should focus on objective knowledge-based assessments to address this concern. Moreover, the
response rate per school ranged from 16% to 65% which demonstrates that the results may not be
fully representative of all final year pharmacy students in this region. Also, the findings may not
be applicable to all students in the United States especially for those students who have advanced
training options at their institutions.
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Conclusion
In all, final year student pharmacists reported varying exposure to pharmacogenomics
content in their pharmacy training; had positive attitudes towards the clinical relevance of the
discipline; yet they expressed low confidence in their readiness to utilize this information in
practice. Hence, practice-based training opportunities taught by well-trained faculty may be
needed to prepare our future pharmacists in this discipline.
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Key Points
1. Final year student pharmacists had positive attitudes and perceptions towards
pharmacogenomics and its clinical relevance even though majority was not ready to
implement related concepts in practice.
2. Student pharmacists were more likely to feel confident in their ability to use
pharmacogenomics in practice after enrolling in pharmacogenomics APPE rotations.
3. Schools of pharmacy should invest in practice-based training opportunities taught by
well-trained faculty to increase readiness to implement related concepts in practice.
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Tables and Figures

Table 1: Demographics Information for the Final Year Pharmacy Student Respondents.

P4 Students (n = 339)
Gender
Female
Male
Prefer not to disclose
Age Range
Less than 21 years
21 - 25 years
26 - 30 years
31 - 40 years
over 40 years
no response

N (%)
213 (62.8)
123 (36.3)
3 (0.90)
1 (0.30)
194 (57.2)
106 (31.3)
33 (9.70)
4 (1.20)
1 (0.30)

Highest level of education before pharmacy School
High School Diploma
Bachelor's degree
Master's degree
Doctorate / JD
Other
No response

147 (43.4)
127 (37.5)
11 (3.20)
31 (9.10)
22 (6.50)
1 (0.30)

Post Graduate Plans
Residency
Fellowship
Community
Hospital
Undecided

83 (24.5)
19 (5.60)
158 (46.6)
32 (9.40)
47 (13.9)
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Table 2: Description of Participating Schools of Pharmacy and their Pharmacogenomics Educational Opportunities.

School/College of Pharmacy
Survey Response Rate:

School C
11.70%
PhD and clinical PharmD
NO

School D
26.90%
Clinical PharmD
NO

School E
27.20%
PhD
NO

School F
57%
RPh and PhD
YES

School G
16.20%
PhD
YES

Other PGx-related Training?

School B
53.10%
PhD
NO
Applied PGx research as an
PGx coursework as part
industry senior scientist
of a Pharmacology Ph.D.
position

PGx certificate program

NO

Molecular and
epigenetics

PGx Post-Doc
Fellowship

PGx PhD and Post-Doc involved in PGx
Fellowship in PGx
research in the past

standalone or integrated?

Stand-alone

Stand-alone

BOTH

Integrated

Integrated

Stand-alone

BOTH

Stand-alone

N/A
Elective

N/A
Required

Pharmacokinetics (2 lectures) Pharmacotherapy
Elective
N/A

Pharmacology
N/A

N/A
Required

Several courses
Required

N/A
Required
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N/A

10 to 15

N/A

N/A

N/A

N/A

N/A

3rd professional year

2nd or 3rd
professional year

2nd professional
year

3rd professional year

3rd professional year

2nd professional year

Terminal Degree
Formal PGx Training

PGx Faculty

If integrated, what course?
If standalone, is it required or an elective?
PGx Didactic Average student per year for the elective
Course
courses

Details
When is the course offered?

Length of course/credits
To identify medications that require or are
recommended by the FDA to have PGx
testing.
To recommend appropriate PGx tests for the
PGx Course medications that require testing.
** Learning To accurately interpret pharmacogenomics
Objectives tests.
To recommend alternative therapies or doses
when required by a PGx test result.
Become familiar with how to access,
interpret and utilize the CPIC guidelines.
PGx APPE Opportunity
PGx APPE** Length of APPE

School A
64.60%
PhD
NO

1st, 2nd, or 3rd
professional year

2nd professional year

School H
39.40%
PhD
NO

one semeste; 2 credit
hours

one semester; 2 credit hours one semester; 2 credit hours N/A

N/A

one semester; 2
credits

one semester; 2
credits

one semester; 2
credits

YES

YES

YES

N/A

YES

N/A

YES

YES

YES

YES

YES

N/A

NO

NO

YES

NO

YES

YES

YES

N/A

NO

NO

YES

NO

YES

YES

YES

N/A

YES

YES

YES

YES

YES
NO
N/A

NO
YES
5 weeks

YES
NO
N/A

N/A
YES
5 weeks

NO
YES
6 weeks

N/A
NO
N/A

YES
NO
N/A

NO
NO
N/A

** The PGx APPE training addresses all the learning objectives listed.
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Table 3: Survey responses from the final year pharmacy students

Perception
of the
clinical
relevance
of PGx

Attitudes
towards
PGx
education

Readiness
to use PGx
knowledge
in practice

Survey Questions
Pharmacogenomics is an integral part
of the pharmacy profession.
Pharmacogenomics may be an integral
part of my practice as a pharmacist.
I may encounter pharmacogenomics
related questions during my practice as
a pharmacist.
Pharmacogenomics is a useful tool that
pharmacists and medical professionals
can use to optimize medication efficacy
and/or prevent adverse events.
Pharmacogenomics has been a
relevant part of my doctor of pharmacy
curriculum.
Pharmacogenomics should be covered
in detail for all colleges and schools of
pharmacy.
Final year (P4) pharmacy students
should be required to have substantial
knowledge of pharmacogenomics prior
to graduation.
Post-graduation, I intend to read up on
pharmacogenomics especially on how
it influences my practice and /or
specialty.
I know at least ten medications that
require or are recommended to have
pharmacogenomics testing as per the
FDA.
I am able to recommend the
appropriate pharmacogenomics test/s
for the medications that require it.
I am able to accurately interpret
pharmacogenomics tests.
Based on the results of a
pharmacogenomics test, I am able to
recommend alternative therapies or
dose changes when required.
I am aware of the Clinical
Pharmacogenetics Implementation
Consortium's (CPIC) guidelines on how
to use genetic information to guide
drug therapy selection/dosing.

Number of Respondents (%)
Strongly
Strongly Disagree
Agree / Agree Neutral
/ Disagree

No
response

214 (63.1)

67 (19.8)

28 (8.26)

30 (8.85)

205 (60.5)

62 (18.3)

42 (12.4)

30 (8.85)

234 (69.0)

45 (13.3)

29 (8.55)

31 (9.14)

273 (80.5)

27 (7.96)

9 (2.65)

30 (8.85)

136 (40.1)

88 (26.0)

96 (28.3)

19 (5.60)

239 (70.5)

67 (19.8)

13 (3.83)

20 (6.00)

175 (51.6)

97 (28.6)

48 (14.2)

19 (5.60)

188 (55.5)

81 (23.9)

51 (15.0)

19 (5.60)

108 (31.9)

55 (16.2)

150 (44.2)

26 (7.67)

72 (21.2)

79 (23.3)

161 (47.5)

27 (7.96)

91 (26.8)

75 (22.1)

147 (43.4)

26 (7.67)

107 (31.6)

82 (24.2)

124 (36.6)

26 (7.67)

55 (16.2)

48 (14.2)

209 (61.7)

27 (7.96)
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Figure 1: The extent of pharmacogenomics education achieved by the final year student
pharmacists at the time of this survey.

Figure 1 Legend:

Percentages were calculated from the "previous exposure to

pharmacogenomics demographic question”. Those who did not answer were excluded from the
ordered categorical variable constructed from these responses. Due to the low number of
respondents who endorsed having genetics major or minor previously (2), that category was also
excluded”.
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Figure 2: Relationship between exposure to pharmacogenomics education and final year
student pharmacists' attitudes towards pharmacogenomics education.
Figure 2 Legend: The effects of exposure to previous pharmacogenomics education on attitudes
towards pharmacogenomics education are displayed as ß values, with 95% confidence intervals
displayed as error bars. The measure of pharmacogenomics training was significantly
associated with more agreement to three of the four questions assessing attitudes towards
pharmacogenomics education: pharmacogenomics had been a relevant part of their curriculum
(Standardized Beta (ß) =0.365, 95% Confidence Interval (CI): 0.252 - 0.477); final year
pharmacy students should be required to have substantial pharmacogenomics knowledge (ß
=0.150, 95% CI: 0.0.039 - 0.260); and I intend to read up on pharmacogenomics after
graduating (ß =0.116, 95% CI: 0.003 - 0.229). It was also suggestively associated with the
fourth question, on agreement that it should be covered in detail in all pharmacy schools (ß
=0.129, 95% CI: -0.005 - 0.262).
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Figure 3: The relationship between exposure to pharmacogenomics education and
readiness to use it in practice.
Figure 3 Legend: Different levels of exposure to pharmacogenomics education are categorized
along the x-axis, and a mean score of PGx readiness by group is displayed on the y-axis, with
error bars corresponding to the standard errors within each group. The score was calculated for
each person by treating agreement with each of the five readiness statements as 1, and
disagreement as -1 (neutral is treated as 0) and summing all five together. The correlation
between level of pharmacogenomics education exposure and readiness score was 0.389 (95%
Confidence Interval: 0.291 - 0.478; R2 = 0.151), suggesting a positive relationship between
more exposure to pharmacogenomics education and increased readiness to use
pharmacogenomics in practice.
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